Artivion, Inc.
NYSE:AORTMedical - Devices
-$0.11 today
- Market cap
- $904.56M
- Beta
- 1.26
- P/E (TTM)
- 86.7
- EPS (TTM)
- $0.24
Volume 0.91M
Average 0.64M
AORT Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Artivion, Inc.NYSE: AORT
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $463K fell 88.2% year over year, behind the +76.9% change in trailing-twelve-month financing cash flow. Sequentially, it fell 80.9% from the prior quarter.
Context
- Financing cash flow amounted to 3.0% of revenue in FY2025, up 2.4 pp from a year earlier.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -88.2% toward the trailing-twelve-month pace of +76.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 13.03M USD
- Year-over-year change
- +491.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.03M | +491.6% |
| FY2024 | 2024-12-31 | 2.2M | +154.7% |
| FY2023 | 2023-12-31 | 865K | +152.8% |
| FY2022 | 2022-12-31 | (1.64M) | +86.6% |
| FY2021 | 2021-12-31 | (12.22M) | — |
Financing Cash Flow vs competitors
How AORT compares with its peers on the latest reported figures
- AORT's LTM Mar 2026 financing cash flow of $9.56M is the smallest of the 11 companies compared; the peer median is $41.03M.
- Its year-over-year change of +76.9% is the 4th highest of 11, against a peer median of -51.5%.
- Financing cash flow amounts to 2.1% of revenue for AORT, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $861.53M | +1082.7% | +75.1% | — | |
| LTM Jun 2026 | $127.85M | +606.1% | — | 8.1% | |
| LTM Jun 2026 | $106M | -161.1% | +3.3% | 7.2% | |
| LTM Jun 2026 | $104.96M | -27.3% | — | 11.7% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $98.85M | -437.4% | -27.4% | 1.5% |
| LTM Jul 2026 | $92.19M | +874.7% | -22.2% | 5.0% | |
| LTM Sep 2026 | $72.44M | -77.8% | +26.1% | 2.5% | |
| LTM Jun 2026 | $40.85M | -75.7% | -2.8% | 9.1% | |
| LTM Mar 2026 | $21.92M | -24.9% | +64.3% | 45.2% | |
| LTM Mar 2026 | $10.12M | -94.3% | +45.8% | 3.1% | |
| LTM Mar 2026 | $9.56M | +76.9% | — | 2.1% | |
| Peer median (excluding AORT) | $41.03M | -51.5% | +14.7% | 7.2% | |
Competitors are the stored peer set for AORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.83M) | (19.19M) | (30.69M) | (13.36M) | 9.77M |
| Depreciation & Amortization | 23.98M | 22.44M | 23.08M | 24.21M | 22.46M |
| Deferred Income Tax | (4.47M) | (1.72M) | (1.39M) | (1.51M) | 37K |
| Stock-Based Compensation | 10.71M | 12.34M | 14.42M | 14.24M | 24.39M |
| Change in Working Capital | (33.23M) | (25.94M) | (16.19M) | (17.24M) | (22.16M) |
| Accounts Receivables | (11.56M) | (13.34M) | (4.05M) | (15.4M) | (7.27M) |
| Inventory | (18.38M) | (8.4M) | (14.36M) | (6.14M) | (15.28M) |
| Accounts Payables | (1.89M) | (1.96M) | 1.68M | 9.5M | 2.18M |
| Other Working Capital | (1.4M) | (2.23M) | 535K | (5.21M) | (1.8M) |
| Other Non-Cash Items | 15.26M | 6.91M | 29.6M | 15.9M | 3.64M |
| Operating Cash Flow | (2.59M) | (5.15M) | 18.83M | 22.24M | 38.13M |
| Capital Expenditures | (13.09M) | (10.72M) | (7.43M) | (11.19M) | (39.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 19M | 0 | 0 | 0 | 0 |
| Other Investing Activities | (249K) | 0 | 6.93M | (17M) | (3M) |
| Investing Cash Flow | 5.66M | (10.72M) | (502K) | (28.19M) | (42.04M) |
| Debt Repayment | (3.09M) | (2.75M) | (2.77M) | (358K) | (2.46M) |
| Common Stock Issued | 0 | 0 | 0 | 5.73M | 13.07M |
| Common Stock Repurchased | (1.91M) | (1.8M) | (559K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.22M) | 2.91M | 4.2M | (3.17M) | 2.42M |
| Financing Cash Flow | (12.22M) | (1.64M) | 865K | 2.2M | 13.03M |
| Effect of Forex Changes | 2.2M | 1.85M | 401K | (1.73M) | 2.32M |
| Net Change in Cash | (6.95M) | (15.66M) | 19.59M | (5.48M) | 11.45M |
| Free Cash Flow | (15.68M) | (15.87M) | 11.4M | 11.05M | (911K) |
Artivion, Inc.
NYSE:AORT
Intrinsic Alpha fair value
Locked
Current Price
$18.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.